从多塞塔克塞尔早期转换为卡巴西塔克塞尔在化耐药前列腺癌中早期切换的有效性
Taketo Kawai1,2, Kazuki Maki2, Satoru Taguchi2
1Department of Urology, International University of Health and Welfare Ichikawa Hospital, Chiba, Japan.
The Prostate
|October 22, 2025
概括
在治疗割抵抗性前列腺癌 (CRPC) 之后,早期切换到cabazitaxel可能会减少副作用并改善无进展生存率 (PFS). 这一策略使得CRPC患者的化疗暴露时间更长.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 卡巴西塔克塞尔对割耐性前列腺癌 (CRPC) 的不良反应比多塞塔克塞尔少.
- 卡巴西塔克塞尔通常保留给那些没有对多塞塔克塞尔反应的患者.
- 这项研究调查了从多塞塔克塞尔早期切换到卡巴西塔克塞尔的好处.
研究的目的:
- 评估早期从多塞塔克塞尔转换为卡巴西塔克塞尔是否能改善CRPC患者的临床结果.
- 为了比较早期切换者和历史非切换组之间的化疗持续时间,周期数和不良事件.
主要方法:
- 患有CRPC的患者在三次多塞塔塞尔循环后 (切换组) 转换为cabazitaxel.
- 一个历史的非切换组在没有早期切换的情况下接受了多塞塔塞尔.
- 使用倾向性得分匹配分析了无进展生存 (PFS),分类器失败的时间和整体生存 (OS).
主要成果:
- 转换组接受了更多的化疗周期,累计持续时间更长.
- 在早期切换组中,周围神经病变的发病率明显较低.
- 早期切换减少了包括疲劳和脱发在内的症状性不良事件,并显著延长了PFS.
结论:
- 在dcetaxel后早期切换到cabazitaxel可能会减少像外围神经病变这样的症状性不良事件.
- 这种策略允许长时间的化疗暴露.
- 早期切换表明CRPC患者的PFS改善的潜力.
更多相关视频
06:44Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
Published on: September 8, 2017
13.9K
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
7.2K
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
01:15Drugs that Stabilize Microtubules
2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K